Effect Of A Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) On Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth And Osteolytic Bone Disease. ASCO 2014.
An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2013.
Preclinical Studies of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity in BPDCN Cell Lines, Primary Tumor, and in an In Vivo Model. ASH 2013.
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity against Chronic Eosinophilic Leukemia. ASH 2013.
SL-401, A Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. ASH 2013.
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients with Advanced Hematological Malignancies. ASCO 2013.
